MAP2K7 and neoplasm: The use of inhibitors such as those targeting BRAF (vemurafenib, dabrafenib) and MEK (trametinib, selumetinib, cobimetinib) in BRAFV600E-positive melanoma resulted in a moderate success of targeted therapies by showing tumor shrinkage and improving patient survival (28–30).